Incyte (ICY) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ICY Analyst Ratings

Moderate Buy

10 Buy

10 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Incyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ICY Stock 12 Month Forecast

Average Price Target

€112.70

▲(7.13% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is €112.70 with a high forecast of €134.44 and a low forecast of €94.54. The average price target represents a 7.13% change from the last price of €105.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"€64","135":"€135","81.75":"€81.8","99.5":"€99.5","117.25":"€117.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":134.43763024999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€134.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.70312152647058,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€112.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.54001095,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€94.54</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,81.75,99.5,117.25,135],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.2,109.29520232692308,111.39040465384615,113.48560698076923,115.5808093076923,117.67601163461538,119.77121396153845,121.86641628846152,123.96161861538461,126.05682094230768,128.15202326923077,130.24722559615384,132.3424279230769,{"y":134.43763024999998,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.2,107.62331704049774,108.04663408099547,108.46995112149321,108.89326816199095,109.31658520248868,109.73990224298642,110.16321928348417,110.5865363239819,111.00985336447964,111.43317040497737,111.85648744547511,112.27980448597285,{"y":112.70312152647058,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.2,106.22615468846153,105.25230937692308,104.27846406538461,103.30461875384616,102.33077344230769,101.35692813076923,100.38308281923076,99.40923750769231,98.43539219615384,97.46154688461539,96.48770157307692,95.51385626153845,{"y":94.54001095,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.74,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.92,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.86,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.24,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.78,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€134.44

Average Price Target€112.70

Lowest Price Target€94.54

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Berens

Leerink Partners

€113.62→€134.44

Buy

27.79%

Upside

Reiterated

08/03/26

Incyte price target raised to $155 from $131 at LeerinkIncyte price target raised to $155 from $131 at Leerink

Mitchell Kapoor

H.C. Wainwright

€130.1

Buy

23.67%

Upside

Reiterated

08/03/26

Analyst Reiterates Buy on Opzelura Strength, Keeps 12-Month Price Target Unchanged at $150

Salim Syed

Mizuho Securities

€104.95→€118.83

Buy

12.95%

Upside

Reiterated

08/03/26

Mizuho Securities Remains a Buy on Incyte (INCY)

Jessica Fye

J.P. Morgan

€95.41→€104.08

Hold

-1.06%

Downside

Assigned

07/30/26

Incyte price target raised to $120 from $110 at JPMorganIncyte price target raised to $120 from $110 at JPMorgan

Srikripa Devarakonda

Truist Financial

―

Hold

―

Reiterated

07/29/26

Analysts Offer Insights on Healthcare Companies: AxoGen (NASDAQ: AXGN) and Incyte (NASDAQ: INCY)

Derek Archila

Wells Fargo

€87.6→€100.61

Hold

-4.36%

Downside

Reiterated

07/29/26

Wells Fargo Sticks to Its Hold Rating for Incyte (INCY)

Salveen Richter

Goldman Sachs

€95.41→€102.35

Hold

-2.71%

Downside

Reiterated

07/29/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (NASDAQ: GOVX), Incyte (NASDAQ: INCY) and Altimmune (NASDAQ: ALT)

Evan Seigerman

BMO Capital

€97.14→€112.75

Hold

7.18%

Upside

Reiterated

07/29/26

Incyte price target raised to $130 from $112 at BMO CapitalIncyte price target raised to $130 from $112 at BMO Capital

Judah Frommer

Morgan Stanley

€90.2→€103.21

Hold

-1.89%

Downside

Reiterated

07/29/26

Incyte price target raised to $119 from $104 at Morgan StanleyIncyte price target raised to $119 from $104 at Morgan Stanley

Michael Schmidt

Guggenheim

€117.96→€130.1

Buy

23.67%

Upside

Reiterated

07/28/26

Analysts Are Bullish on These Healthcare Stocks: Universal Health (UHS), Incyte (INCY)

Etzer Darout

Barclays

€116.22→€120.56

Buy

14.60%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (Other OTC: CSBTF), Centene (NYSE: CNC) and Incyte (NASDAQ: INCY)

Marc Frahm

TD Cowen

€107.55→€119.69

Buy

13.78%

Upside

Reiterated

07/28/26

Analysts Conflicted on These Healthcare Names: Baxter International (NYSE: BAX), Incyte (NASDAQ: INCY) and Argenx Se (NASDAQ: ARGX)

Jay Olson

Oppenheimer

€92.81→€104.08

Buy

-1.06%

Downside

Reiterated

07/28/26

Incyte price target raised to $120 from $107 at OppenheimerIncyte price target raised to $120 from $107 at Oppenheimer

Brian Abrahams

RBC Capital

€85.87→€94.54

Hold

-10.13%

Downside

Reiterated

07/28/26

RBC Capital Sticks to Their Hold Rating for Incyte (INCY)

Ashwani Verma

UBS

€98.01

Hold

-6.84%

Downside

Reiterated

07/28/26

Incyte Rally Caps Near-Term Upside; Ashwani Verma Reiterates Hold With Unchanged $113 Price Target

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Berens

Leerink Partners

€113.62→€134.44

Buy

27.79%

Upside

Reiterated

08/03/26

Incyte price target raised to $155 from $131 at LeerinkIncyte price target raised to $155 from $131 at Leerink

Mitchell Kapoor

H.C. Wainwright

€130.1

Buy

23.67%

Upside

Reiterated

08/03/26

Analyst Reiterates Buy on Opzelura Strength, Keeps 12-Month Price Target Unchanged at $150

Salim Syed

Mizuho Securities

€104.95→€118.83

Buy

12.95%

Upside

Reiterated

08/03/26

Mizuho Securities Remains a Buy on Incyte (INCY)

Jessica Fye

J.P. Morgan

€95.41→€104.08

Hold

-1.06%

Downside

Assigned

07/30/26

Incyte price target raised to $120 from $110 at JPMorganIncyte price target raised to $120 from $110 at JPMorgan

Srikripa Devarakonda

Truist Financial

―

Hold

―

Reiterated

07/29/26

Analysts Offer Insights on Healthcare Companies: AxoGen (NASDAQ: AXGN) and Incyte (NASDAQ: INCY)

Derek Archila

Wells Fargo

€87.6→€100.61

Hold

-4.36%

Downside

Reiterated

07/29/26

Wells Fargo Sticks to Its Hold Rating for Incyte (INCY)

Salveen Richter

Goldman Sachs

€95.41→€102.35

Hold

-2.71%

Downside

Reiterated

07/29/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (NASDAQ: GOVX), Incyte (NASDAQ: INCY) and Altimmune (NASDAQ: ALT)

Evan Seigerman

BMO Capital

€97.14→€112.75

Hold

7.18%

Upside

Reiterated

07/29/26

Incyte price target raised to $130 from $112 at BMO CapitalIncyte price target raised to $130 from $112 at BMO Capital

Judah Frommer

Morgan Stanley

€90.2→€103.21

Hold

-1.89%

Downside

Reiterated

07/29/26

Incyte price target raised to $119 from $104 at Morgan StanleyIncyte price target raised to $119 from $104 at Morgan Stanley

Michael Schmidt

Guggenheim

€117.96→€130.1

Buy

23.67%

Upside

Reiterated

07/28/26

Analysts Are Bullish on These Healthcare Stocks: Universal Health (UHS), Incyte (INCY)

Etzer Darout

Barclays

€116.22→€120.56

Buy

14.60%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (Other OTC: CSBTF), Centene (NYSE: CNC) and Incyte (NASDAQ: INCY)

Marc Frahm

TD Cowen

€107.55→€119.69

Buy

13.78%

Upside

Reiterated

07/28/26

Analysts Conflicted on These Healthcare Names: Baxter International (NYSE: BAX), Incyte (NASDAQ: INCY) and Argenx Se (NASDAQ: ARGX)

Jay Olson

Oppenheimer

€92.81→€104.08

Buy

-1.06%

Downside

Reiterated

07/28/26

Incyte price target raised to $120 from $107 at OppenheimerIncyte price target raised to $120 from $107 at Oppenheimer

Brian Abrahams

RBC Capital

€85.87→€94.54

Hold

-10.13%

Downside

Reiterated

07/28/26

RBC Capital Sticks to Their Hold Rating for Incyte (INCY)

Ashwani Verma

UBS

€98.01

Hold

-6.84%

Downside

Reiterated

07/28/26

Incyte Rally Caps Near-Term Upside; Ashwani Verma Reiterates Hold With Unchanged $113 Price Target

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

ZURAZura Bio

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

3 Months

Michael SchmidtGuggenheim

Success Rate

19/26 ratings generated profit

Average Return

+8.47%

Copying Michael Schmidt's trades and holding each position for 3 Months would result in 73.08% of your transactions generating a profit, with an average return of +8.47% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

18/18 ratings generated profit

Average Return

+34.90%

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +34.90% per trade.

2 Years

Tazeen AhmadBank of America Securities

Success Rate

18/18 ratings generated profit

Average Return

+48.21%

Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +48.21% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ICY Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ICY has received 36 Buy Ratings, 36 Hold Ratings, and 2 Sell Ratings. ICY average Analyst price target in the past 3 months is 112.70.

Each month's total comprises the sum of three months' worth of ratings.

ICY Financial Forecast

ICY Earnings Forecast

Next quarter’s earnings estimate for ICY is -€2.41 with a range of -€3.56 to €1.71. The previous quarter’s EPS was €2.68. ICY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 44.90% of the time in the same period. In the last calendar year ICY has Performed in-line its overall industry.

ICY Sales Forecast

Next quarter’s sales forecast for ICY is €1.28B with a range of €1.24B to €1.31B. The previous quarter’s sales results were €1.45B. ICY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 58.33% of the time in the same period. In the last calendar year ICY has Performed in-line its overall industry.

ICY Stock Forecast FAQ

What is DE:ICY’s average 12-month price target, according to analysts?

Based on analyst ratings, Incyte Corp’s 12-month average price target is 112.70.

What is DE:ICY’s upside potential, based on the analysts’ average price target?

Incyte Corp has 7.13% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Incyte Corp a Buy, Sell or Hold?

Incyte Corp has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 10 hold ratings and 0 sell ratings.

What is Incyte Corp’s share price target?

The average share price target for Incyte Corp is 112.70. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €134.44 ,and the lowest forecast is €94.54. The average share price target represents 7.13% Increase from the current price of €105.2.

What do analysts say about Incyte Corp?

Incyte Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Incyte Corp?

To buy shares of DE:ICY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Incyte (ICY) Stock Forecast & Price Target

ICY Analyst Ratings

ICY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Incyte

ICY Analyst Recommendation Trends

ICY Financial Forecast

ICY Earnings Forecast

ICY Sales Forecast

ICY Stock Forecast FAQ

Detailed List of Analyst Forecasts